Positron emission tomography measures of benzodiazepine receptors in Huntington's disease
dc.contributor.author | Holthoff, Vjera A. | en_US |
dc.contributor.author | Koeppe, Robert A. | en_US |
dc.contributor.author | Frey, Kirk A. | en_US |
dc.contributor.author | Penney, John B. | en_US |
dc.contributor.author | Markel, Dorene S. | en_US |
dc.contributor.author | Kuhl, David E. | en_US |
dc.contributor.author | Young, Anne B. | en_US |
dc.date.accessioned | 2007-04-06T18:54:54Z | |
dc.date.available | 2007-04-06T18:54:54Z | |
dc.date.issued | 1993-07 | en_US |
dc.identifier.citation | Holthoff, Vjera A.; Koeppe, Robert A.; Frey, Kirk A.; Penney, John B.; Markel, Dorene S.; Kuhl, David E.; Young, Anne B. (1993)."Positron emission tomography measures of benzodiazepine receptors in Huntington's disease." Annals of Neurology 34(1): 76-81. <http://hdl.handle.net/2027.42/50353> | en_US |
dc.identifier.issn | 0364-5134 | en_US |
dc.identifier.issn | 1531-8249 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/50353 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8390806&dopt=citation | en_US |
dc.description.abstract | We performed positron emission tomographic (PET) measurements of the regional distribution volume of benzodiazepine receptors and regional glucose metabolism in 6 drug-free patients with early Huntington's disease following injection of [ 11 C] flumazenil, a nonsubtype selective central benzodiazepine receptor antagonist, and 18 F-2-fluoro-2-deoxy- D -glucose, respectively. Flumazenil data were analyzed with a recently developed two-compartment, two-parameter tracer kinetic model. Benzodiazepine receptor density is related to distribution volume for flumazenil. In comparison with a group of healthy volunteers, benzodiazepine receptor density was significantly decreased in the caudate nucleus. Glucose metabolism was significantly reduced not only in the caudate nucleus but also in the putamen and thalamus. The changes in benzodiazepine receptor density observed in the caudate nucleus are commensurate with data obtained in postmortem autoradiographic studies of receptor density. Based on such postmortem studies we also anticipated changes in putamen and thalamic benzodiazepine receptor density. However, relatively little is known on receptor changes in early Huntington's disease, because the autoradiographic data available were obtained mostly in patients with advanced disease. The decreased glucose metabolism in the caudate and putamen agrees well with previously published results of PET studies, whereas metabolic impairment of the thalamus has not yet been described in Huntington's disease. The present study suggests that regional metabolism and Γ-aminobutyric acid (GABA)-benzodiazepine receptor changes in subcortical structures of patients with early Huntington's disease do not occur with the same time course: Caudate benzodiazepine receptor density is already severely impaired when other subcortical structures reveal only minor abnormalities. Impairment of neuronal metabolism seems to predate GABA/benzodiazepine receptor changes since the putamen and thalamus demonstrate metabolic impairment without detectable loss of benzodiazepine receptor density. | en_US |
dc.format.extent | 660244 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Neuroscience, Neurology, and Psychiatry | en_US |
dc.title | Positron emission tomography measures of benzodiazepine receptors in Huntington's disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Psychiatry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor, MI ; Max-Planck-Institut fÜr Neurologische Forschung, KÖln, Federal Republic of Germany ; Max-Planck-Institut fÜr Neurologische Forschung, Gleuelerstr. 50, 5000 KÖln 41, FRG | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor, MI ; Department of Neurology, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nuclear Medicine, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Neurology, University of Michigan Medical School, Ann Arbor, MI | en_US |
dc.identifier.pmid | 8390806 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/50353/1/410340114_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/ana.410340114 | en_US |
dc.identifier.source | Annals of Neurology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.